22 min
Agitation in Alzheimer’s Dementia – Patients & Caregivers PsychU Community Podcast
-
- Health & Fitness
Listen to Amica Simmons-Yon, PharmD, PhD and Aneta Fornal, PharmD as they spill the tea on Agitation in Alzheimer’s Dementia with special guest, Marc Agronin, MD. During this episode, Dr. Agronin defines agitation, discusses management strategies, and the impact of agitation on both patients and caregivers. Lastly, Dr. Agronin will also share some key resources with listeners and where they can read more about this hot topic!
Featuring:
• Marc Agronin, MD; Chief Medical Officer, Miami Jewish MIND Institute; Associate Professor of Psychiatry & Neurology, University of Miami School of Medicine
• Amica Simmons-Yon, PharmD, PhD; Senior Medical Science Liaison, OPDC
• Aneta Fornal, PharmD; Medical Science Director, OPDC
Resources
• PsychU Infographic - Agitation Associated With Alzheimer’s Dementia (AAD): A Focus On Stigma: https://go.psychu.org/KmQZ
• PsychU Webinar - Addressing Inequalities In Agitation Among Disinvested Communities With Alzheimer’s Disease: https://go.psychu.org/KmRF
• PsychU Webinar - New ICD-10-CM Dementia Codes For Agitation In Alzheimer’s Dementia: https://go.psychu.org/KmRL
• PsychU Video - Agitation Associated With Alzheimer’s Dementia: Mechanism Of Disease: https://go.psychu.org/KmRR
• PsychU Webinar - Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia: https://go.psychu.org/KmRU
• PsychU Webinar - Pathophysiology Of Agitation Associated with Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems: https://go.psychu.org/KmRY
Marc Agronin, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc
Amica Simmons-Yon & Aneta Fornal are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.
Listen to Amica Simmons-Yon, PharmD, PhD and Aneta Fornal, PharmD as they spill the tea on Agitation in Alzheimer’s Dementia with special guest, Marc Agronin, MD. During this episode, Dr. Agronin defines agitation, discusses management strategies, and the impact of agitation on both patients and caregivers. Lastly, Dr. Agronin will also share some key resources with listeners and where they can read more about this hot topic!
Featuring:
• Marc Agronin, MD; Chief Medical Officer, Miami Jewish MIND Institute; Associate Professor of Psychiatry & Neurology, University of Miami School of Medicine
• Amica Simmons-Yon, PharmD, PhD; Senior Medical Science Liaison, OPDC
• Aneta Fornal, PharmD; Medical Science Director, OPDC
Resources
• PsychU Infographic - Agitation Associated With Alzheimer’s Dementia (AAD): A Focus On Stigma: https://go.psychu.org/KmQZ
• PsychU Webinar - Addressing Inequalities In Agitation Among Disinvested Communities With Alzheimer’s Disease: https://go.psychu.org/KmRF
• PsychU Webinar - New ICD-10-CM Dementia Codes For Agitation In Alzheimer’s Dementia: https://go.psychu.org/KmRL
• PsychU Video - Agitation Associated With Alzheimer’s Dementia: Mechanism Of Disease: https://go.psychu.org/KmRR
• PsychU Webinar - Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia: https://go.psychu.org/KmRU
• PsychU Webinar - Pathophysiology Of Agitation Associated with Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems: https://go.psychu.org/KmRY
Marc Agronin, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc
Amica Simmons-Yon & Aneta Fornal are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved.
22 min